Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.84 |
| ▸ | BCHE | P06276 | 3/20 | 0.64 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038344 | 1.00 | CHRM2 (0.84) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4917384 | 1.00 | CHRM2 (0.84) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4916089 | 0.98 | CHRM2 (0.81) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4913847 | 0.92 | CHRM2 (0.77) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4915334 | 0.92 | CHRM2 (0.77) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4914669 | 0.92 | CHRM2 (0.77) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL1134127 | 0.90 | CHRM2 (0.74) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL10384415 | 0.89 | CHRM2 (0.73) | CHRM2BCHESCN8AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6122475 | 0.89 | CHRM2 (0.72) | CHRM2BCHESCN8AKMT2AMEN1 | |
| SCHEMBL4511091 | 0.88 | CHRM2 (0.71) | CHRM2BCHESCN8AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390483-B1 | ENCAPSULATION | PROCTER & GAMBLE (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10864167-B2 | Encapsulation | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3390483-A1 | ENCAPSULATION | The Procter and Gamble Company (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3368207-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180235893-A1 | ENCAPSULATION | THE PROCTER & GAMBLE COMPANY | 2018-08-23 | — | — | US | disclosed |
| US-9937477-B2 | Encapsulation | WATERTITE PRODUCTS, INC. | 2018-04-10 | — | — | US | disclosed |
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017074995-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017074997-A1 | ENCAPSULATION | ENCAPSYS, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170113200-A1 | Encapsulation | Encapsys,LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8552078-B2 | Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235893-A1 | ENCAPSULATION | ACR, ACMSD, SAMM50 | CHRM2 1120/4885BCHE 1469/4885SCN8A 2806/4885 |
| US-10864167-B2 | Encapsulation | ACR, MPHOSPH6, ACMSD | CHRM2 993/4885BCHE 1742/4885SCN8A 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.